• Xilio Therapeutics Inc XLO.OQ reported quarterly adjusted earnings of 81 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-2.80. The lone analyst forecast for the quarter was for a loss of $1.68 per share.

• Revenue rose 693.9% to $13.69 million from a year ago; analysts expected $7.96 million.

• Xilio Therapeutics Inc's reported EPS for the quarter was 81 cents​.

• The company reported quarterly net income of $10.36 million.

• Xilio Therapeutics Inc shares had fallen by 12.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Xilio Therapeutics Inc is $28.00, about 71.9% above its last closing price of $7.86

This summary was machine generated from LSEG data March 23 at 01:52 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)